GlassScriptPhysician profile
Evan Siegel
NPI 1578562617
$594,473.46
in general payments reported to CMS, 2019-2025
27 companies · $92K in 2025
The $92K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $84K · 2021: $72K · 2022: $95K · 2023: $97K · 2024: $46K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $105K · Consulting Fee: $78K · Honoraria: $25K · Travel and Lodging: $21K · Food and Beverage: $6,340 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,697.50 |
| Consulting Fee | $78,428.33 |
| Honoraria | $24,775.50 |
| Travel and Lodging | $20,608.64 |
| Food and Beverage | $6,339.69 |
| Education | $342.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233,090.41 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $95,240.63 | 2019-2025 | Bimzelx, Cimzia |
| Amgen INC. | $60,069.60 | 2019-2025 | Krystexxa, Tavneos, Otezla |
| Janssen Biotech, INC. | $49,462.99 | 2019-2025 | Simponi Aria, Tremfya, Stelara |
| Horizon Therapeutics Plc | $38,214.62 | 2019-2023 | Krystexxa |
| United Rheumatology | $28,921.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $27,825.35 | 2019-2024 | Cosentyx |
| Lilly USA, LLC | $18,122.07 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $18,000.99 | 2019-2025 | Sotyktu |
| Pfizer INC. | $10,505.97 | 2019-2020 | |
| Ucb Sa | $6,548.52 | 2023-2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $6,033.00 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,400.00 | 2025 | |
| Janssen Global Services, LLC | $350.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $272.17 | 2022-2025 | Saphnelo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $140.93 | 2021-2023 | |
| Pacira Therapeutics, INC. | $92.56 | 2019 | |
| Celgene Corporation | $31.01 | 2019 | |
| Radius Health, INC. | $28.70 | 2019 | |
| Glaxosmithkline, LLC. | $27.69 | 2019 | |
| Boston Scientific Corporation | $22.11 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.91 | 2019 | |
| Depuy Synthes Sales INC. | $15.55 | 2019 | |
| Sobi, INC | $13.81 | 2019 | |
| Genentech USA, INC. | $13.46 | 2024 | Actemra |
| Merck Sharp & Dohme LLC | $12.71 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Siegel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.